• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

蛋白酶体抑制剂N-{N-[N-乙酰基-(S)-亮氨酰]-(S)-亮氨酰}正亮氨酸醛（ALLN）的晶体结构

Crystal structure of N-{N-[N-acetyl-(S)-leuc-yl]-(S)-leuc-yl}norleucinal (ALLN), an inhibitor of proteasome.

作者信息

Czerwinski Andrzej, Basava Channa, Dauter Miroslawa, Dauter Zbigniew

机构信息

Peptides International, Inc., 11621 Electron Drive, Louisville, KY 40299, USA.

Leidos Biomedical Research Inc., Basic Science Program, Argonne National Laboratory, Argonne, IL 60439, USA.

出版信息

Acta Crystallogr E Crystallogr Commun. 2015 Feb 7;71(Pt 3):254-7. doi: 10.1107/S2056989015002091. eCollection 2015 Mar 1.

DOI:10.1107/S2056989015002091
PMID:25844180
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4350719/
Abstract

The title compound, C20H37N3O4, also known by the acronym ALLN, is a tripeptidic inhibitor of the proteolytic activity of the proteasomes, enzyme complexes implicated in several neurodegenerative diseases and other disorders, including cancer. The crystal structure of ALLN, solved from synchrotron radiation diffraction data, revealed the mol-ecules in extended conformation of the backbone and engaging all peptide N and O atoms in inter-molecular hydrogen bonds forming an infinite anti-parallel β-sheet.

摘要

标题化合物C20H37N3O4，其简称为ALLN，是蛋白酶体蛋白水解活性的三肽抑制剂，蛋白酶体是一种与多种神经退行性疾病及其他病症（包括癌症）相关的酶复合物。通过同步辐射衍射数据解析得到的ALLN晶体结构表明，分子主链呈伸展构象，且所有肽的N原子和O原子参与分子间氢键形成无限的反平行β-折叠。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/4350719/9336563312a7/e-71-00254-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/4350719/5dc03a16a573/e-71-00254-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/4350719/305661e6e4fb/e-71-00254-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/4350719/9336563312a7/e-71-00254-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/4350719/5dc03a16a573/e-71-00254-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/4350719/305661e6e4fb/e-71-00254-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/baf1/4350719/9336563312a7/e-71-00254-fig3.jpg

相似文献

1
Crystal structure of N-{N-[N-acetyl-(S)-leuc-yl]-(S)-leuc-yl}norleucinal (ALLN), an inhibitor of proteasome.蛋白酶体抑制剂N-{N-[N-乙酰基-(S)-亮氨酰]-(S)-亮氨酰}正亮氨酸醛（ALLN）的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Feb 7;71(Pt 3):254-7. doi: 10.1107/S2056989015002091. eCollection 2015 Mar 1.
2
Crystal structures of three N-(aryl-sulfon-yl)-4-fluoro-benzamides.三种N-（芳基磺酰基）-4-氟苯甲酰胺的晶体结构
Acta Crystallogr E Crystallogr Commun. 2016 Mar 31;72(Pt 4):575-82. doi: 10.1107/S2056989016005089. eCollection 2016 Apr 1.
3
Crystal structure of 2-hy-droxy-imino-2-(pyridin-2-yl)-N'-[1-(pyridin-2-yl)ethyl-idene]acetohydrazide.2-羟基-亚氨基-2-(吡啶-2-基)-N'-[1-(吡啶-2-基)亚乙基]乙酰肼的晶体结构
Acta Crystallogr Sect E Struct Rep Online. 2014 Nov 29;70(Pt 12):584-6. doi: 10.1107/S1600536814025793. eCollection 2014 Dec 1.
4
Crystal structure of (E)-2-({[2-(1,3-dioxan-2-yl)phen-yl]imino}-meth-yl)phenol.（E）-2-（{[2-（1,3-二氧六环-2-基）苯基]亚氨基}-甲基）苯酚的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Apr 30;71(Pt 5):o357-8. doi: 10.1107/S2056989015008051. eCollection 2015 May 1.
5
Crystal structure of (E)-2-{[(4-anilinophen-yl)imino]-meth-yl}phenol.（E）-2-{[（4-苯胺基苯基）亚氨基]甲基}苯酚的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Jan 1;71(Pt 1):28-30. doi: 10.1107/S2056989014026309.
6
Crystal structure of 4-{[(1H-1,2,4-triazol-1-yl)meth-yl]sulfan-yl}phenol.4-{[(1H-1,2,4-三唑-1-基)甲基]硫基}苯酚的晶体结构
Acta Crystallogr Sect E Struct Rep Online. 2014 Sep 13;70(Pt 10):o1106. doi: 10.1107/S1600536814019965. eCollection 2014 Oct 1.
7
Crystal structure of di-chlorido-{2-[(2-hy-droxyeth-yl)(pyridin-2-ylmeth-yl)amino]-ethano-lato-κ(4) N,N',O,O'}iron(III) dihydrate from synchrotron data.基于同步辐射数据的二氯代-{2-[(2-羟乙基)(吡啶-2-基甲基)氨基]乙醇酸根-κ(4)N,N',O,O'}铁(III)二水合物的晶体结构
Acta Crystallogr Sect E Struct Rep Online. 2014 Oct 11;70(Pt 11):334-6. doi: 10.1107/S1600536814022089. eCollection 2014 Nov 1.
8
Crystal structure of (2-benzyl-oxy-pyrimidin-5-yl)boronic acid.（2-苄氧基嘧啶-5-基）硼酸的晶体结构
Acta Crystallogr Sect E Struct Rep Online. 2014 Nov 15;70(Pt 12):o1259-60. doi: 10.1107/S1600536814024519. eCollection 2014 Dec 1.
9
Crystal structure of 7-{[bis-(pyridin-2-ylmeth-yl)amino]-meth-yl}-5-chloro-quinolin-8-ol.7-{[双-(吡啶-2-基甲基)氨基]-甲基}-5-氯喹啉-8-醇的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Nov 28;71(Pt 12):1545-7. doi: 10.1107/S2056989015022410. eCollection 2015 Dec 1.
10
Crystal structure of 4-meth-oxy-N-[(pyrrolidin-1-yl)carbo-thio-yl]benzamide.4-甲氧基-N-[(吡咯烷-1-基)碳硫酰基]苯甲酰胺的晶体结构
Acta Crystallogr E Crystallogr Commun. 2015 Mar 4;71(Pt 4):o225-6. doi: 10.1107/S2056989015003813. eCollection 2015 Apr 1.

引用本文的文献

1
The Toxic Effect of ALLN on Primary Rat Retinal Neurons.ALLN对原代大鼠视网膜神经元的毒性作用。
Neurotox Res. 2016 Oct;30(3):392-406. doi: 10.1007/s12640-016-9624-6. Epub 2016 May 19.

本文引用的文献

1
Development of proteasome inhibitors as research tools and cancer drugs.蛋白酶体抑制剂作为研究工具和癌症药物的开发。
J Cell Biol. 2012 Nov 12;199(4):583-8. doi: 10.1083/jcb.201210077.
2
The proteasome in health and disease.蛋白酶体在健康和疾病中的作用。
Curr Pharm Des. 2013;19(6):1010-28.
3
Proteasome inhibitors: an expanding army attacking a unique target.蛋白酶体抑制剂：一支不断壮大的攻击独特靶点的队伍。
Chem Biol. 2012 Jan 27;19(1):99-115. doi: 10.1016/j.chembiol.2012.01.003.
4
The 26S proteasome complex: an attractive target for cancer therapy.26S蛋白酶体复合物：癌症治疗的一个有吸引力的靶点。
Biochim Biophys Acta. 2012 Jan;1825(1):64-76. doi: 10.1016/j.bbcan.2011.10.003. Epub 2011 Oct 18.
5
Proteasome structure, function, and lessons learned from beta-lactone inhibitors.蛋白酶体结构、功能及β-内酰胺抑制剂的启示
Curr Top Med Chem. 2011 Dec;11(23):2850-78. doi: 10.2174/156802611798281320.
6
Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.天然产物抑制泛素-蛋白酶体系统治疗癌症。
Planta Med. 2010 Aug;76(11):1064-74. doi: 10.1055/s-0029-1240901. Epub 2010 Feb 25.
7
Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.蛋白酶体抑制剂：药物化学的最新进展和新视角。
Curr Top Med Chem. 2010;10(3):232-56. doi: 10.2174/156802610790725515.
8
Calpains: attractive targets for the development of synthetic inhibitors.钙蛋白酶：合成抑制剂开发的有吸引力的靶标。
Curr Top Med Chem. 2010;10(3):270-93. doi: 10.2174/156802610790725489.
9
Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.蛋白酶体模型与肽醛抑制剂 MG132 和 MG101 的共价复合物：对接和分子动力学研究。
J Mol Model. 2009 Dec;15(12):1481-90. doi: 10.1007/s00894-009-0515-0. Epub 2009 May 14.
10
Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches.多种疾病状态下泛素-蛋白酶体系统功能障碍：治疗方法
Bioessays. 2008 Nov;30(11-12):1172-84. doi: 10.1002/bies.20852.